Absorption of Meloxicam on Porous Calcium Silicate: Characterization and tablet formulation

AAPS PharmSciTech

Volumn 6, Issue 4, 2005, Pages

  Sharma, Sameer ^a   Sher, Praveen ^a   Badve, Shraddha ^a   Pawar, Atmaram P ^a  

^a BHARATI VIDYAPEETH DEEMED UNIVERSITY   (India)

Author keywords

Adsorption; Dissolution; Florite RE; Meloxicam; Microparticles

Indexed keywords

CALCIUM SILICATE; EXCIPIENT; MELOXICAM; CALCIUM DERIVATIVE; SILICATE; THIAZINE DERIVATIVE; THIAZOLE DERIVATIVE;

ARTICLE; DRUG ADSORPTION; DRUG SOLUBILITY; INFRARED SPECTROMETRY; TABLET DISINTEGRATION TIME; TABLET FORMULATION; THERMAL ANALYSIS; X RAY DIFFRACTION; ADSORPTION; CHEMISTRY; COMPARATIVE STUDY; ENTERIC COATED TABLET; POROSITY;

ADSORPTION; CALCIUM COMPOUNDS; CHEMISTRY, PHARMACEUTICAL; POROSITY; SILICATES; TABLETS, ENTERIC-COATED; THIAZINES; THIAZOLES;

EID: 29244438801     PISSN: 15309932     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/pt060476     Document Type: Article

References (24)

1. Amidon GL, Lennernäs H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12:413-420.
2. Meriani F, Coceani N, Sirotti C, Voinovich D, Grassi M. In vitro nimesulide absorption from different formulations. J Pharm Sci. 2004;93:540-552.
3. Perrut M, Jung J, Leboeuf F. Enhancement of dissolution rate of poorly-soluble active ingredients by supercritical fluid processes Part I. Micronization of neat particles. Int J Pharm. 2005;288:3-10.
4. Kinoshita M, Baba K, Nagayasu A, et al. Improvement of solubility and oral bioavailability of a poorly water-soluble drug, TAS-301, by its melt-adsorption on a porous calcium silicate. J Pharm Sci. 2002;91:362-370.
5. Ambike AA, Mahadik KR, Paradkar A. Stability study of amorphous valdecoxib. Int J Pharm. 2004;282:151-162.
6. Chowdary KPR, Hymavathi R. Enhancement of dissolution rate of meloxicam. Ind J Pharm Sci. 2001;63:150-154.
7. Smirnova I, Suttiruengwong S, Seiler M, Arlt W. Dissolution rate enhancement by adsorption of poorly soluble drugs on hydrophilic silica aerogels. Pharm Dev Technol. 2004;9:443-452.
8. Streubel A, Siepmann J, Bodmeier R. Floating matrix tablet based on low density foam powder: effects of formulation and processing parameters on drug release. Eur J Pharm Sci. 2003;18:37-45.
9. Yuasa H, Takashima Y, Kanaya Y. Studies on the development of intragastric floating and sustained release preparation. I. Application of calcium silicate as a floating carrier. Chem Pharm Bull (Tokyo). 1996;44:1361-1366.
10. Streubel A, Siepmann J, Bodmeier R. Floating microparticles based on low density foam powder. Int J Pharm. 2002;241:279-292.
11. Ito Y, Arai H, Uchino K, Iwasaki K, Shibata N, Takada K. Effect of adsorbents on the absorption of lansoprazole with surfactant. Int J Pharm. 2005;289:69-77.
12. Salis A, Sanjust E, Solinas V, Monduzzi M. Characterization of Accurel MP 1004 polypropylene powder and its use as a support for lipase immobilization. J Mol Cat B Enz. 2003;24-25:75-82.
13. Byrne RS, Deasy PB. Use of commercial porous ceramic particles for sustained drug delivery. Int J Pharm. 2002;246:61-73.
14. Yuasa H, Asahi D, Takashima Y, Kanaya Y, Shinozawa K. Application of calcium silicate for medicinal preparation. I. Solid preparation adsorbing an oily medicine to calcium silicate. Chem Pharm Bull (Tokyo). 1994;42:2327-2331.
15. Yuasa H, Akutagawa M, Hashizume T, Kanaya Y. Studies on internal structure of tablets. VI. Stress dispersion in tablets by excipients. Chem Pharm Bull (Tokyo). 1996;44:378-382.
16. Kinoshita M, Baba K, Nagayasu A, et al. Highly stabilized amorphous 3-bis(4-methoxyphenyl)methylene-2-indolinone (TAS-301) in melt-adsorbed products with silicate compounds. Drug Dev Ind Pharm. 2003;29:523-529.
17. Jackson RL, Jason MD. Analgesic-antipyretic and anti-inflammatory agents and drugs employed in the treatment of gout. In: Hardman JG, Limbird LE, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. New York, NY: McGraw-Hill; 2001:713-714.
18. Naidu NB, Chowdary KP, Murthy KV, Satyanarayana V, Hayman AR, Becket G. Physicochemical characterization and dissolution properties of meloxicam-cyclodextrin binary systems. J Pharm Biomed Anal. 2004;35:75-86.
19. Ghorab MM, Abdel-Salem HM, El-Sayad MA, Mekhel MM. Tablet formulation containing meloxicam and β-cyclodextrin: mechanical characterization and bioavailability evaluation. AAPS PharmSciTech. 2004;5:E59.
20. Seedher N, Bhatia S. Solubility enhancement of Cox-2 inhibitors using various solvent systems. AAPS PharmSciTech. 2003;4:E33.
21. Cantera RG, Leza MG, Bachiller CM. Solid phases of tenoxicam. J Pharm Sci. 2002;91:2240-2251.
22. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline. Impurities: guideline for residual solvents Q3C. Geneva, Switzerland: ICH; 1997.
23. Costa P, Lobo JMS. Modeling and comparison of dissolution profiles. Eur J Pharm Sci. 2001;13:123-133.
24. Charumanee S, Okonoki S, Sirithunyalug J. Improvement of the dissolution rate of piroxicam by surface solid dispersion. CMU J. 2004;3:77-84.